Key result
Proximal tubule-specific megalin deletion or administration of the megalin inhibitor cilastatin ameliorated rhabdomyolysis-induced AKI in mice by preserving GFR and reducing tubular injury.
Why the study?
Rhabdomyolysis causes severe AKI and death, but specific pharmacologic therapy is unavailable and supportive care is difficult to provide in austere environments.
Does megalin deletion or cilastatin administration prevent rhabdomyolysis-induced AKI in a mouse model?
Does megalin deletion or cilastatin administration prevent rhabdomyolysis-induced AKI in a mouse model?
In a mouse model, megalin deletion or inhibition with cilastatin ameliorated rhabdomyolysis-induced AKI, suggesting a potential novel therapeutic target.
No takes yet. Share an insight, caveat, or question.
Megalin blockade may mitigate rhabdomyolysis AKI in mice; leaves open whether cilastatin benefits humans.
Matsushita et al. (2021) studied Rhabdomyolysis-induced AKI. Proximal tubule-specific megalin deletion and Cilastatin vs. Littermate controls / wild-type mice was evaluated on GFR, proximal tubule injury, and renal apoptosis. Proximal tubule-specific megalin deletion or administration of the megalin inhibitor cilastatin ameliorated rhabdomyolysis-induced AKI in mice by preserving GFR and reducing tubular injury.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: